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First-episode schizophrenia (FES) spectrum disorders are 
associated with pronounced cognitive dysfunction across all 
domains. However, less is known about the course of cognitive 
functioning, following the first presentation of psychosis, and 
the relationship of cognition to clinical course during initial 
treatment. The present longitudinal study examined the mag-
nitude of neurocognitive impairment, using the MATRICS 
Consensus Cognitive Battery, in patients experiencing their 
first episode of psychosis at baseline and after 12 weeks of 
randomized antipsychotic treatment with either aripiprazole 
or risperidone. At baseline, FES patients evidenced marked 
impairments in cognitive functioning. Notably, performance 
on the mazes task of planning and reasoning significantly 
predicted the likelihood of meeting stringent criteria for 
positive symptom remission during the first 12 weeks of the 
trial. Performance on indices of general cognitive function, 
working memory, and verbal learning improved over time, 
but these improvements were mediated by improvements in 
both positive and negative symptoms. We did not detect any 
differential effects of antipsychotic medication assignment 
(aripiprazole vs risperidone) on cognitive functioning. Our 
results suggest that a brief paper-and-pencil measure reflect-
ing planning/reasoning abilities may index responsivity to 
antipsychotic medication. However, improvements in cogni-
tive functioning over time were related to clinical symptom 
improvement, reflecting “pseudospecificity.”
Key words: cognition/general cognitive function/ 
psychosis/planning/aripiprazole/risperidone
Introduction
In recent years, cognitive dysfunction has increasingly 
been considered a core feature of schizophrenia and 
related psychotic disorders.1–3 Moderate deficits are 
observed years before the onset of full psychotic symp-
toms, escalating in severity during adolescence.4,5 By 
the onset of psychosis, deficits are nearly as severe as 
those observed in patients with chronic illness; stud-
ies of patients in the first episode of illness consistently 
demonstrate a generalized deficit of 1 SD or more below 
the mean performance of healthy individuals.6–8 While 
the presence of severe cognitive deficits in first-episode 
schizophrenia (FES) spectrum disorders is well estab-
lished, the relationship between these deficits and early 
treatment course remains unclear. Most of the studies 
reviewed in recent meta-analyses of FES patients utilized 
a cross-sectional design.7,8 Moreover, many of these stud-
ies examined patients after clinical stabilization, several 
months after initiation of antipsychotic treatment.
Due to the relative difficulty in conducting large-scale, 
controlled treatment trials, only a few prospective stud-
ies have examined the course of cognitive deficits in FES 
patients undergoing initial treatment with antipsychotic 
medications. Consequently, several critical questions 
remain unresolved. First, it is unclear to what extent cogni-
tive performance at baseline can predict clinical response to 
antipsychotic medication. Approximately 40% of patients 
will fail to respond to the initial antipsychotic trial9 (see also 
Robinson et al,10 this issue), and prognostic biomarkers are 
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lacking. In treatment of chronic schizophrenia, the risk of 
nonresponse can often be detected within the first 2 weeks 
of treatment,11 but early nonresponse is not prognostic 
for FES patients.12 Baseline predictive indicators can help 
explicate the neurobiology of antipsychotic response and, 
ideally, could guide deployment of clinical resources, given 
that clinical nonresponse accounts for the large majority 
of total health resource utilization associated with psy-
chosis.13 The Center for Intervention Development and 
Advanced Research (CIDAR) at the Zucker Hillside 
Hospital (ZHH; Malhotra,14 this issue) was designed with 
the primary aim of identifying biomarkers that can predict 
and explain the heterogeneity of response to antipsychotic 
treatment in FES.
A second unresolved question is the degree to which 
antipsychotic medication can ameliorate cognitive defi-
cits in FES. The first prospective studies examining cogni-
tive performance before and after 12 weeks of exposure 
to initial treatment demonstrated modest improvements 
(effect sizes between 0.2 and 0.4 SDs) across most cogni-
tive domains.15–17 However, a comparison with healthy 
controls assessed across the same two time-points indi-
cated that practice effects likely accounted for nearly all of 
the gains.18 The MATRICS Consensus Cognitive Battery 
(MCCB) was specifically designed with alternate forms to 
minimize practice effects for use in controlled treatment 
trials,19 but to date it has never been examined in an acute 
trial of FES patients; the present study is the first to do so.
Moreover, the extent to which cognitive improve-
ment after treatment may be secondary to clinical 
changes (reduction of positive and/or negative symp-
toms) remains an open question. While studies in chronic 
patients typically demonstrate modest but significant 
correlations between cognition and clinical symptom-
atology (both cross-sectionally and over time20), prior 
studies in FES patients have yielded mixed results. Some 
studies have suggested that correlations between cogni-
tive improvement and symptom reduction were specific 
to first-generation antipsychotics only,16,17 while others 
have demonstrated broad correlations between cognitive 
and clinical change.21 Moreover, cross-sectional and lon-
gitudinal studies in FES patients have consistently dem-
onstrated correlations of cognitive deficits with negative 
symptoms.6,22–24
Finally, while studies of cognitive effects have typically 
demonstrated broad similarities across various second-
generation antipsychotic agents,15,21 aripiprazole has 
not yet been well studied. Only one comparative study 
has been conducted in a FES cohort; in an unblinded 
6-month trial conducted in China, aripiprazole demon-
strated broadly similar effects to risperidone, except for 
a failure to enhance processing speed.25 By contrast, in 
a comparison of 4 second-generation antipsychotics in 
a (mostly) chronic cohort, Riedel et  al26 reported that 
aripiprazole demonstrated the greatest ability to improve 
reaction time and attention. Two other studies in chronic 
patients27,28 have suggested that aripiprazole may have dis-
tinctive cognitive properties (both positive and negative) 
as a result of its unique mechanism of action (partial ago-
nism rather than pure antagonism at the dopamine D2 
receptor). Moreover, aripiprazole (but not risperidone) 
has demonstrated modestly beneficial effects on negative 
symptoms (Robinson et al,10 this issue), which may be 
critical to cognitive change.29 Thus, it is plausible that dif-
ferential cognitive effects of aripiprazole vs risperidone 
may also be observed.
The present study was, therefore, designed to prospec-
tively test several unanswered questions in the treatment 
of FES: (1) Can baseline cognitive measures predict clini-
cal response to antipsychotics?; (2) Can antipsychotic 
medications ameliorate cognitive deficits in first-episode 
patients, independent of practice effects and clinical 
changes?; and (3) Are there differences in the cognitive 
effects of aripiprazole vs risperidone? As noted above, the 
present study utilized the MCCB, which is designed to 
reliably and efficiently assess each of 7 dissociable cog-
nitive factors that have been replicably identified in the 
schizophrenia literature.30 These questions were addressed 
in the context of a 12-week, blinded controlled study of 
aripiprazole vs risperidone, as described in greater detail 
elsewhere in this volume.10
Methods
Full methodological details regarding the 12-week ran-
domized clinical trial can be found in the accompanying 
manuscript by Ref: 10. Details of the ZHH CIDAR initia-
tive that are principally relevant to the current study are 
described below.
Participants
Table  1 provides demographic information about the 
sample. The current study included 175 participants (73% 
male; mean age of 22.55 ± 5.67 y) at study entry with a 
schizophrenia spectrum disorder (schizophrenia, n = 123 
[67%]; schizophreniform disorder, n = 35 [23%]; schizoaf-
fective disorder, n = 5 [3%]; or psychotic disorder not oth-
erwise specified, n = 12 [7%]). Participants were recruited 
from a consortium of 10 collaborative medical centers 
including 8 in the greater New York City area, as well as 
San Antonio, Texas and Calgary, Alberta, Canada. The 
sample was racially/ethnically and socioeconomically 
diverse, as study sites were located in urban or suburban 
areas and served diverse communities. Study data were 
collected from December of 2005 through April of 2013. 
Study inclusion and exclusion criteria are summarized in 
supplementary table 1. Inclusion criteria required all par-
ticipants to have less than 2 weeks of prior antipsychotic 
exposure and 28% of our sample (n = 49) was completely 
antipsychotic medication naive. Any antipsychotics 
being taken at the time of study entry were discontin-
ued and participants started randomized medication 
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without a withdrawal period. After complete descrip-
tion of the study, written informed consent was obtained 
from all adult participants. For participants younger than 
18 years, written parental consent and written participant 
assent were obtained. The study was conducted under the 
auspices of the Feinstein Institute for Medical Research 
Institutional Review Board (IRB) as the coordinating 
center and the IRBs of the clinical sites.
Clinical Assessment Measures
Initial diagnosis for eligibility was established with 
the Structured Clinical Interview of Axis I  DSM-IV 
Disorders (SCID).31 These data were later reviewed in a 
consensus conference for final diagnostic assignment.32 
Assessments done at baseline, weekly for 4 weeks, and 
then every 2 weeks included: Brief  Psychiatric Rating 
Scale-Anchored version (BPRS-A)33; Hillside clinical tri-
als version of the Schedule for Assessment of Negative 
Symptoms (SANS)34; and the Clinical Global Impression 
Scale (CGI).35
Treatment Protocol
The acute treatment study phase lasted 12 weeks 
(85.2 ± 5.7 d elapsed from baseline to follow-up on aver-
age). Participants were stratified by site, previous antipsy-
chotic exposure (none vs any), and diagnosis (psychotic 
disorder Not Otherwise Specified vs other eligible diagno-
ses) and were randomly assigned on a 1:1 basis to double-
masked treatment with either aripiprazole (5–30 mg/d) or 
risperidone (1–6 mg/d).
Antipsychotic Treatment Response Criteria
Response to antipsychotic treatment was based on a 
priori criteria that was defined as follows: (1) a rating 
of 3 (“mild”) or less on all of the following items of the 
BPRS-A: conceptual disorganization, grandiosity, halluci-
natory behavior, unusual thought content and (2) a CGI 
Improvement rating of “much improved” or “very much 
improved.” These criteria were required to be sustained 
on 2 consecutive rating assessments for a patient to be 
considered as a responder. Time of response was the date 
of the first of the 2 consecutive ratings meeting these 
criteria.
Cognitive Evaluation With the MCCB
The MCCB is a battery of neuropsychological tests that 
were rigorously identified for inclusion as a standard-
ized approach to the serial assessment of key cognitive 
deficits in medication trials for patients with schizo-
phrenia and related disorders.36 The MCCB includes 7 
cognitive domains: Speed of Processing (semantic flu-
ency [animal naming], Brief  Assessment of Cognition 
Table 1. Demographic and Clinical Characteristics of Full Sample (N = 175) at Baseline, and Those Who Did (N = 109) and Did Not 
(N = 66) Complete the NP Evaluation at Both Time Points
Full Sample
Completed  
Full NP
Did Not 
Complete NP
N = 175 N = 109 N = 66
N % N % N % P
Male 128 73.14 82 0.75 46 0.70 .424
Racial/ethnic minority 135 77.14 84 0.77 51 0.77 .975
Randomized to aripiprazole 93 53.14 60 0.55 33 0.50 .517
Randomized to risperidone 82 46.86 49 0.45 33 0.50
Mean SD Mean SD Mean SD
Age (y) 22.55 5.67 22.10 5.40 23.29 6.07 .179
Paternal education 13.18 3.34 12.69 3.44 14.31 2.81 .014
Paternal Hollingshead social class 3.92 1.71 3.99 1.63 3.76 1.90 .506
Maternal education 12.95 2.97 12.72 3.08 13.46 2.69 .186
Maternal Hollingshead social class 3.78 2.02 3.90 2.08 3.54 1.89 .363
WRAT-3 estimated premorbid IQ 97.07 12.41 95.79 12.99 99.13 11.21 .127
MCCB general composite, baseline 33.52 9.36 33.70 9.62 33.22 9.01 .749
Handedness (percent right-handed) 0.89 0.32 0.85 0.36 0.95 0.21 .093
BPRS Positive symptoms 14.55 3.59 14.48 3.35 14.67 3.97 .742
SANS Affective flattening 1.80 0.97 1.92 1.02 1.62 0.84 .050
SANS Alogia 2.03 1.06 2.08 1.08 1.94 1.04 .387
SANS Avolition 2.08 1.03 2.21 1.07 1.88 0.92 .041
SANS Anhedonia 2.13 0.97 2.15 0.98 2.11 0.95 .782
Note: BPRS, Brief  Psychiatric Rating Scale; MCCB, MATRICS Consensus Cognitive Battery; NP, neuropsychological; SANS, Scale for 
the Assessment of Negative Symptoms; WRAT-3, Wide-Range Achievement Test, 3rd edition.
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in Schizophrenia [BACS] symbol coding, and part A of 
the Trail Making test); Working Memory (letter-num-
ber span and spatial span); Reasoning and Problem 
Solving (Neuropsychological Assessment Battery [NAB] 
Mazes); Verbal Learning (Hopkins Verbal Learning Test-
Revised [HVLT-R]); Visual Learning (Brief  Visuospatial 
Memory Test-Revised [BVMT-R]); Attention/Vigilance 
(Continuous Performance Test, Identical Pairs [CPT-IP]); 
and Social Cognition (Mayer-Salovey-Caruso Emotional 
Intelligence Test [MSCEIT], Managing Emotions). In 
addition to the 7 domain scores, the MCCB provides 
an overall composite score that indexes general cogni-
tive performance across domains. Trained psychometri-
cians administered the battery, and administration of all 
MCCB tests adhered to procedures described in the test 
manual.36
Statistical Procedures
Quality Control. Raw data for continuous variables 
were plotted using standard procedures (eg, histograms 
and Q-Q plots) and examined for normality. Extreme 
outlier data points (defined as a value whose distance 
from the nearest quartile was greater than 1.5 times the 
interquartile range in either direction) were removed.37 
Cognitive performance data were adjusted for age, sex, 
site (using 2 site indicator variables; one representing the 
largest site [ZHH] as the reference group and one repre-
senting the Calgary site, which had significantly higher 
cognitive scores compared to all other sites, as the refer-
ence group), and racial/ethnic minority status.
Baseline Cognitive Predictors of Response to 
Treatment. Initial analyses compared the rates of anti-
psychotic treatment response (based on criteria defined 
above) over the 12-week trial as a function of cognitive 
performance at study entry using the MCCB. These anal-
yses used Cox regression procedures, under a propor-
tional hazards model, to assess clinical response status 
and time as a function of baseline cognitive status and 
relevant covariates.
Change in Cognitive Performance in Relation to 
Antipsychotic Medication and Psychosis Symptomatology. 
Next, we examined whether cognitive performance in 
FES is: (1) stable, declines, or improves after 3 months 
time; (2) dissimilar in trajectory depending on whether 
patients were randomized to aripiprazole (a partial 
dopamine agonist) vs risperidone (a dopamine antag-
onist); and (3) mediated by improvements in positive 
and negative symptoms (ie, if  changes could be due 
to “pseudospecificity,” simply reflecting antipsychotic 
effects on symptoms). Analyses of  longitudinal pat-
terns of  change in cognitive performance as a function 
of  antipsychotic drug and psychosis symptomatology 
were carried out using a series of  linear mixed-model 
approaches in SAS.38 Factors in the models were time, 
medication type, time × medication type interaction, 
the sum of  BPRS remission items, and the 4 global 
SANS scores. A random intercept in the mixed models 
was used to account for correlation of  measurements 
over time among the participants; the correlational 
type was assumed to be unstructured. The difference in 
slopes of  the outcomes between the 2 treatment groups 
was assessed using a group-by-time interaction term in 
the mixed models.
Results
Premorbid IQ estimated from the word reading subtest of 
the Wide-Range Achievement Test, 3rd edition (WRAT-
3) was in the average range (mean = 97.07 ± 12.41), and 
participants were predominantly right-handed (89% ± 
32%). As shown as part of table  1, 109 of 175 partici-
pants completed cognitive evaluations at baseline and 
follow-up. Completers and noncompleters were not sig-
nificantly different in key clinical variables including age, 
race/ethnicity, antipsychotic type, IQ, and most symptom 
measures, except for affective flatting and avolition, which 
were slightly higher in completers. As shown in table 2, 
our FES cohort demonstrated marked impairments in 
cognitive functioning across domains on the MCCB at 
baseline, with an average T score of 33.8 ± 11.8, more than 
1.5 SDs below the general population mean. On average, 
scores improved slightly from baseline to 3-month fol-
low-up across domains, although performance was still 
markedly impaired with an average T score of 35.5 ± 11.1. 
Deficits in processing speed were the most pronounced 
of all domains, and social cognition was least impaired 
relative to the other domains. Table 2 also provides sum-
maries of the raw score data from each individual test 
across time.
Baseline Predictors of Response
In Cox regression analyses, after controlling for poten-
tial demographic confounds, as well as the sum of BPRS 
remission items and SANS negative symptoms at study 
entry, general cognitive performance at baseline signifi-
cantly predicted 12-week response rates to antipsychotic 
treatment (Wald statistic = 4.62, P = .032). Further, add-
ing this term significantly improved model fit (χ2 change: 
4.73, P = .030). To determine if  a specific process drove 
the general cognitive effect, subsequent analyses exam-
ined the 7 MCCB domains individually for association to 
treatment response. After strict Bonferroni correction for 
multiple comparisons, baseline performance in the MCCB 
reasoning domain (as measured by the NAB mazes sub-
test) was a significant and robust predictor of response to 
antipsychotic treatment (Wald statistic = 10.02, P = .002) 
when entered into the model (χ2 change: 9.94, P = .002). 
As shown in table 3, in both instances, individuals who 
1241
Cognitive Function in First-Episode Psychosis 
evidenced better cognitive functioning in general and spe-
cifically in the domain of reasoning at baseline responded 
faster to subsequent antipsychotic treatment as compared 
to patients who were relatively more impaired.
We then examined the specificity of reasoning relative 
to the other cognitive domains. After controlling for age, 
sex, minority status, and site on step 1, baseline SANS 
negative symptoms on step 2, and the 6 other MCCB 
cognitive domains on step 3, adding reasoning on step 
4 significantly improved the model fit (χ2 change = 8.03, 
P  =  .005), and reasoning continued to evidence a sig-
nificant association to treatment response (B  =  0.051, 
SE  =  0.018, Wald  =  8.08, P  =  .004). Thus, reasoning/
problem solving at baseline specifically predicted treat-
ment response, as no other cognitive domains were sig-
nificant (P > .29; table  3). Further, the association of 
general cognitive function to treatment response was pri-
marily driven by reasoning/planning performance on the 
mazes task.
To better understand the association between MCCB 
reasoning and treatment response, we examined the tra-
jectory of sustained response rates across the 12-week 
treatment phase. In order to perform a graphical exami-
nation, we classified individuals as high performers on 
NAB mazes (defined as those scoring at or above the 75th 
percentile within the sample), average performers (those 
who scored below the 75th percentile and above the 25th 
percentile), and low performers (those who performed at 
or below the 25th percentile). As shown in figure 1, only 
20% of patients in the low performing group responded 
favorably to antipsychotic treatment by the midpoint of 
the trial (week 6) compared to 60% of the high perform-
ing group. By week 12, 40% of the low group responded 
to treatment compared to 80% of patients in the high 
group. Response rates for the average/middle group fell 
in-between the high and low groups.
Changes in Cognitive Performance
During the 3 months of treatment, general cognitive func-
tion improved by approximately 2 points, working mem-
ory improved by 5 points, and verbal learning improved 
by 2 points. No other MCCB domain evidenced signifi-
cant change from baseline to follow-up (supplementary 
table 2). In the sections below, we report the results of 
examining how these changes in cognition were influ-
enced by clinical variables, specifically medication type 
and symptom change.
Comparison of Aripiprazole and Risperidone in 
Cognitive Performance Change
No differential effects of aripiprazole vs risperidone on 
cognitive performance were observed. Specifically, there 
were no statistically significant antipsychotic medication 
type (aripiprazole vs risperidone) × time interactions for 
any cognitive variables (all P > .35).
Table 2. MCCB Standardized Domain Scores and Raw Subtest Scores at Baseline
Baseline Week 12
N Mean SD Min. Max. N Mean SD Min. Max.
MCCB domain (T scores)
 General cognitive function 172 33.39 9.39 8.20 57.00 109 35.49 8.61 10.50 58.29
 Speed of processing 170 30.18 15.05 −3.00 71.00 108 30.96 12.25 −5.00 64.00
 Working memory 165 32.45 14.38 −10.00 63.00 106 37.92 12.38 6.00 76.00
 Reasoning/problem solving 164 36.85 10.85 15.00 62.00 105 38.75 10.83 16.00 63.00
 Verbal learning 172 35.39 8.79 17.00 72.00 111 37.56 8.94 19.00 67.00
 Visual learning 168 32.51 12.47 −3.00 61.00 109 33.98 12.51 −1.00 59.00
 Attention/vigilance 125 32.12 10.51 6.00 57.00 88 31.85 11.64 6.00 62.00
 Social cognition 152 37.21 13.07 4.00 67.00 101 37.43 11.99 14.00 63.00
MCCB subtest (raw scores)
 BACS symbol coding 172 44.93 13.71 11.00 80.00 111 45.86 11.66 9.00 80.00
 Semantic fluency (animals) 172 19.09 7.20 3.00 38.00 109 18.91 5.76 8.00 41.00
 Trails A 170 40.13 19.57 16.72 109.12 111 37.01 14.91 15.56 83.65
 Letter-number span 166 11.96 4.38 1.00 22.00 107 13.07 3.62 4.00 21.00
 Spatial span 170 13.68 4.22 3.00 25.00 111 15.41 4.01 7.00 28.00
 NAB mazes 164 16.29 6.84 0.00 26.00 105 17.69 6.28 0.00 26.00
 HVLT-R total score, trials 1–3 172 20.33 5.74 3.00 35.00 111 21.79 5.55 5.00 34.00
 BVMT-R total score, trials 1–3 168 19.80 7.02 0.00 35.00 109 20.70 7.07 1.00 35.00
 CPT-IP dʹ 125 1.95 0.72 −0.07 3.64 88 1.95 0.76 0.27 3.94
 MSCEIT managing emotions 152 84.44 11.47 54.54 109.15 101 83.97 10.84 54.58 107.96
Note: Domain scores are presented as T scores (M = 50, SD = 10) and domain subtest scores are presented as raw data scores (eg, 
number of seconds to complete Trails A). BACS, Brief  Assessment of Cognition in Schizophrenia; BVMT-R, Brief  Visuospatial 
Memory Test - Revised; CPT-IP, Continuous Performance Test - Identical Pairs; HVLT-R, Hopkins Verbal Learning Test - Revised; 
MCCB, MATRICS Consensus Cognitive Battery; NAB, Neuropsychological Assessment Battery; MSCEIT, Mayer-Salovey-Caruso 
Emotional Intelligence Test.
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Changes in Cognitive Performance in Relation to 
Symptom Improvement
As described above and in supplementary table 2, general 
cognitive function, working memory, and verbal learn-
ing improved from baseline to 12-week follow-up. To test 
whether these improvements were dependent upon reduc-
tions in clinical symptomatology, we conducted a series 
of mediation analyses. For these analyses, we employed 
the causal-steps approach,39,40 which states that 4 steps 
in the causal process must be true for full mediation to 
be present: (1) The total effect of the predictor on the 
outcome must be significant; (2) The effect of the predic-
tor on the mediator must be significant; (3) The effect of 
the mediator on the outcome controlling for the predic-
tor must be significant; and (4) The direct effect of the 
predictor on the outcome adjusting for the mediator must 
be nonsignificant.39,40 We used the BPRS remission items 
and SANS global measures of affective flattening, alogia, 
avolition-apathy, and asociality-anhedonia as mediating 
variables in these models, adding them after we examined 
the main, unconditional effect of antipsychotic treatment.
Details of  the mediation analysis are provided in fig-
ure 1 and supplementary table 3. In all cases, changes in 
cognitive performance were either partially or fully medi-
ated by changes in BPRS remission scores and/or global 
alogia as rated on the SANS. Specifically, improvements 
in general cognitive functioning were partially mediated 
by changes in positive symptoms and fully mediated 
by improvements in alogia. Improvements in working 
memory were fully mediated by reductions in BPRS 
remission scores and partially mediated by reductions in 
alogia. Finally, the mediating effect of  BPRS remission 
scores on improvements in verbal learning was incon-
clusive because the direct effect of  BPRS on verbal 
learning controlled for time was not significant; how-
ever, improvements in verbal learning were fully medi-
ated by reductions in alogia. These results are displayed 
pictorially in figure 2, which show (1) that antipsychotic 
medication type had no differential affect on cogni-
tion and (2) that the simple slopes of  the change from 
baseline to follow-up flatten out over time after covary-
ing for clinical improvement. Additional results of  this 
analysis are presented in supplementary table 4 for the 
other cognitive domains. Notably, after controlling for 
symptoms, social cognition declined significantly over 
time (P = .032).
Table 3. Baseline Cognitive Predictors of Treatment Response
Variable B SE Wald P value OR 95% CI lower 95% CI upper
Block 1 Sex −0.050 0.023 4.807 .028 0.951 0.909 0.995
Age 0.311 0.269 1.338 .247 1.365 0.806 2.311
Minority status 0.179 0.294 0.372 .542 1.196 0.673 2.127
Site indicator 1 (ZHH) −0.028 0.242 0.013 .909 0.973 0.605 1.563
Site indicator 2 (Calgary) 1.347 0.653 4.251 .039 3.844 1.069 13.825
Block 2 BPRS Positive symptoms −0.048 0.036 1.826 .177 0.953 0.889 1.022
SANS Affective flattening 0.029 0.126 0.054 .816 1.030 0.804 1.318
SANS Alogia 0.037 0.127 0.086 .770 1.038 0.809 1.332
SANS Avolition 0.058 0.147 0.158 .691 1.060 0.795 1.414
SANS Anhedonia −0.215 0.167 1.66 .198 0.807 0.582 1.119
Block 3 General cognitive function 0.03 0.014 4.622 .032 1.03 1.003 1.059
Block 1 Age −0.064 0.033 3.723 .054 0.938 0.879 1.001
Sex 0.206 0.370 0.309 .578 1.229 0.595 2.539
Minority status 0.818 0.401 4.166 .041 2.265 1.033 4.968
Site indicator 1 (ZHH) −0.059 0.305 0.037 .847 0.943 0.519 1.714
Site indicator 2 (Calgary) 1.535 0.706 4.725 .030 4.642 1.163 18.533
Block 2 BPRS Positive symptoms −0.101 0.048 4.477 .034 0.904 0.823 0.993
SANS Affective flattening −0.037 0.151 0.060 .806 0.964 0.717 1.295
SANS Alogia 0.034 0.172 0.039 .843 1.035 0.739 1.448
SANS Avolition 0.138 0.184 0.562 .453 1.148 0.801 1.645
SANS Anhedonia −0.334 0.204 2.686 .101 0.716 0.481 1.068
Block 3 Speed of processing 0.002 0.016 0.009 .926 1.002 0.970 1.034
Working memory 0.018 0.017 1.038 .308 1.018 0.984 1.053
Verbal memory 0.000 0.021 0.000 .987 1.000 0.960 1.041
Visual memory 0.007 0.020 0.113 .737 1.007 0.968 1.047
Attention/vigilance −0.019 0.018 1.079 .299 0.981 0.947 1.017
Social cognition −0.013 0.013 0.895 .344 0.987 0.962 1.014
Block 4 Reasoning/problem solving 0.051 0.018 8.081 .004 1.053 1.016 1.091
Note: The upper half  of the table displays the results of general cognitive function, and the lower half  of the table displays the results of 
reasoning after controlling for the other 6 cognitive domains. B, regression coefficient. Bold values indicate significant P values for Table 
3; BPRS, Brief  Psychiatric Rating Scale; SANS, Scale for the Assessment of Negative Symptoms; SE, standard error of B; ZHH, Zucker 
Hillside Hospital.
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Discussion
In this study, we examined baseline cognitive predictors 
of antipsychotic treatment response in a large sample 
of medication-naive or minimally treated FES patients. 
We found that better general cognitive functioning at 
baseline, which was driven by performance on a test of 
planning and reasoning, was associated with a faster rate 
of positive symptom response. We also compared the 
effectiveness of aripiprazole and risperidone in improv-
ing cognitive function, and our results indicate that dif-
ferential medication effects were not detectable. Lastly, 
small but significant improvements in general cognitive 
function, working memory, and verbal learning were seen 
over time, but these findings were mediated by improve-
ments in clinical symptomatology.
The most striking result of our study was the ability of 
baseline cognitive performance, specifically the MCCB 
reasoning subtest, to predict 12-week clinical response to 
risperidone or aripiprazole. Our clinical response mea-
sure was strictly defined as an absence of psychotic-level 
positive symptoms observed over 2 consecutive assess-
ments (see Ref: 10, this issue). As demonstrated in figure 1, 
patients in the top quartile of scores on MCCB reason-
ing were twice as likely to respond as those in the bot-
tom quartile. Notably, our results were highly specific to 
the reasoning domain score: (1) Similar results were not 
observed for other cognitive domains and (2) Multiple 
regression demonstrated no attenuation of results for the 
reasoning test when all other domain scores were entered 
into the model first. This specificity is striking, given that 
the large majority of the cognitive variance in schizo-
phrenia is accounted for by generalized, as opposed to 
specific, deficits.41,42
While pretreatment cognitive performance has not 
been widely studied as a clinically relevant prognostic 
biomarker, a few studies have suggested that this may 
be a promising avenue for future research. For example, 
in an early study of FES patients treated with fluphen-
azine, we demonstrated that an “attention” domain score 
(which included working memory measures as well) sig-
nificantly predicted positive symptom response within 
the first year.43 More recently, a small (n = 28) naturalis-
tic study indicated that first-episode patients with higher 
baseline scores on MCCB attention and verbal memory 
scales (but not reasoning) were more likely to meet remis-
sion criteria after 6 months of treatment.44 Another small 
study (n  =  55, divided into 3 medication groups) also 
found that verbal memory, as well as a novel measure 
of planning, predicted acute (8 wk) positive symptom 
response.45 Differing sample characteristics and test bat-
teries may account for the failure to converge on a single 
prognostic measure, but collectively these studies strongly 
suggest that brief  paper-and-pencil measures of neuro-
cognitive functioning may provide significant prognostic 
information.
Given the relative paucity of functional neuroimaging 
studies examining maze performance, which forms the 
basis of the MCCB reasoning scale, a neurobiological 
Fig. 1. Result of Cox regression analysis of MATRICS Consensus Cognitive Battery reasoning/problem solving performance at baseline 
in relation to 12-week treatment response rates. As can be seen, ~50% of the patients who performed relatively well on the task at 
baseline (defined as those scoring at or above the >75th percentile within the sample) successfully responded to antipsychotic treatment 
after 6 weeks, whereas only ~20% of poor performers (ie, those who performed at or below the 25th percentile) met criteria after the same 
period of time.
1244
J. W. Trampush et al
interpretation of this result is not straightforward. To 
our knowledge, only 1 neuroimaging study has been con-
ducted using this paradigm; as expected, results dem-
onstrated a robust activation of a dorsal frontoparietal 
attention network.46 Notably, the study also found acti-
vations of the basal ganglia and cortical motor areas, 
despite using a nonmotoric (imaginary performance only) 
version of the task. Relatedly, specific deficits in maze 
performance were reported in a study of neurological 
patients with basal ganglia infarcts.47 Thus, it is possible 
that MCCB reasoning performance may serve to index 
dopamine-sensitive frontostriatal circuitry relevant to the 
mechanism of action of antipsychotic medications. Such 
a conclusion is consistent with our recent observation that 
frontostriatal connectivity, measured with resting-state 
functional magnetic resonance imaging, is a powerful 
(sensitivity = 80% and specificity = 75%) and replicable 
prognostic biomarker of antipsychotic response in both 
first-episode and multiepisode patients.48
As noted, we found changes in general cognition, 
working memory, and verbal learning that were highly 
significant for a time effect when no symptom covari-
ates were included, but these associations became non-
significant when time-varying symptom dimensions were 
included. In all cases, BPRS remission score and SANS 
global alogia were consistently significant in the models, 
implicating a mediation effect of these symptoms on cog-
nition.39 However, it should be noted that such “pseudo-
specificity” (ie, cognitive improvement that could result 
from reductions in other aspects of the illness) cannot be 
fully explicated with post hoc statistical approaches.49
Although the introduction of second-generation anti-
psychotics held the promise of nootropic effects, our 
longitudinal cognitive data are consistent with a growing 
body of evidence that second-generation antipsychotics 
provide no specific cognitive benefit.50 While several cog-
nitive scores improved modestly over the course of our 
12-week trial, gains were entirely eliminated when control-
ling for changes in positive and negative symptoms. These 
results are consistent with other recent studies reporting 
a significant correlation between cognitive change and 
symptom remission in FES patients.21,44,51 Indeed, 1 study 
concluded that verbal memory was a state marker of psy-
chosis remission52; our use of a mediation model provides 
formal statistical support for this assertion.
Our results do not support a special role for aripip-
razole, as compared to other second-generation anti-
psychotic agents, in the treatment of cognitive deficits. 
Despite a putative difference in mechanism of action, 
there is no difference in the effects of aripiprazole and 
risperidone on cognitive performance, just as there was 
no difference in positive symptom response (Ref: 10, this 
issue). Differences in negative symptom change and 
motoric side effects reported elsewhere in this issue were 
not reflected in cognitive scores in any domain.
Several limitations of the present study should be 
noted. First, although comparisons between completers 
and noncompleters suggested that the 2 groups did not 
differ on most clinical and demographic variables, pater-
nal education was higher in noncompleters, and SANS 
global affect and avolition were lower in noncompleters. 
However, it is unlikely that these results influenced our 
findings. Second, we did not include a control group 
to examine practice effects. However, the MCCB was 
designed to ameliorate this potential confound, and the 
fact that no cognitive domain change scores were signifi-
cant after controlling for symptom change suggests that 
practice effects were limited. Nonetheless, it is plausible 
Fig. 2. Results of mediation analysis of clinical symptoms on cognitive change. Improvements in clinical symptoms partially and/or fully 
mediated improvements in (a) general cognition, (b) working memory, and (c) verbal learning.
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that the extent of overall change in the MCCB reflected 
learning/practice effects, and that reduction of psychosis 
may permit patients to successfully learn from practice. 
In the schizophrenia literature, psychotic symptomatol-
ogy is not strongly correlated with concurrent measures 
of cognitive performance,53 but it may more strongly 
interfere with learning ability over time, with significant 
implications for cognitive remediation.54 An alternative 
interpretation is that the ability to solve problems (as 
measured by the mazes subtest of the MCCB) predicts 
the ability to learn with practice, which may or may not 
be mediated by clinical response. Finally, our mediation 
models were not designed to explain the direction of the 
cognitive-symptom change interactions, although it is 
intuitive that symptom reduction causally preceded cog-
nitive improvement.
Nevertheless, the present results suggest that planning 
and reasoning skills in FES might hold prognostic value 
in helping to determine which patients are likely to rapidly 
benefit from second-generation antipsychotic treatment. 
Moreover, severe cognitive deficits remain a substantial 
problem in the treatment of FES, and novel pharmacologic 
and/or behavioral strategies are needed to ameliorate them.
Supplementary Material
Supplementary material is available at http://schizophre-
niabulletin.oxfordjournals.org.
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